^
Association details:
Biomarker:No biomarker
Cancer:Colon Cancer
Regimen:FOLFOX (5-fluorouracil + leucovorin calcium + oxaliplatin)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Title:

Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Published date:
07/20/2020
Excerpt:
Recommendations: Combinations of fluoropyrimidines, either 5-FU or capecitabine, and oxaliplatin constitute the bases for stage III colon cancer adjuvant treatment [I, A; European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) v.1.1 score: B]....Patients with high-risk stage II colon cancer may be considered for 3 months of CAPOX, as the IDEA-pooled analysis showed non-inferiority of 3 months of CAPOX and inferiority of 3 months of FOLFOX when compared with 6 months of FOLFOX, with all the limitations of post-hoc analyses [II, B].
DOI:
10.1016/j.annonc.2020.06.022
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
...the panel recommends chemotherapy corresponding to initial therapy for metastatic disease (eg, FOLFIRI, FOLFOX, or CAPEOX chemotherapy alone or with bevacizumab; FOLFIRI or FOLFOX with panitumumab or cetuximab; FOLFOXIRI alone or with bevacizumab)